Biotechnology
Sanyou Bio Launches SAI-DA 1.0, the AI-Drug Accelerator
SHANGHAI, May 20, 2026 /PRNewswire/ -- Sanyou Bio today announced the launch of SAI-DA 1.0 (Sanyou AI-Drug Accelerator). The platform builds on the company's AI-STAL (AI Super-Trillion Antibody Library), which serves as a vast molecular resource bank of super-trillion-scale molecules, SAI-DA 1.0 ...
2026-05-20 22:00
6051
METiS TechBio to Present Late-Breaking Data on Near-Complete Cardiomyocyte Delivery at CRS 2026
BEIJING, HANGZHOU, China and CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a global leader in AI-powered drug delivery innovation, today announced that new preclinical data from its heart-targeted LNP program has been selected for a Late-Breaking oral presentation at the...
2026-05-20 18:57
6770
Haier Biomedical Publishes 2025 Sustainability Report: Committed to Building a Platform for Technology, Industry and Social Responsibility
QINGDAO, China, May 20, 2026 /PRNewswire/ -- Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, has released its 2025 Sustainability Report, providing a comprehensive overview of the company's measurable progress achieved in environmental, social, and governance...
2026-05-20 12:23
7550
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery
Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening HOUSTON, May 19, 2026 /PRNewswire/ -- Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, is proud to announce the launch of its innovative XPressMAX™ Cell-Free ...
2026-05-19 23:45
9067
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
NANJING, China, May 18, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received approval from the Center for Drug Evaluation (CDE) of Chi...
2026-05-19 09:35
7116
Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases
* Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza * Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis NEW YORK and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Accro Bio...
2026-05-19 08:00
6777
Major breakthrough of Sanyou Biopharmaceuticals AI-STAL
SHANGHAI, May 18, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals announced today that its independently developed AI-STAL has undergone a significant upgrade, successfully achieving a qualitative leap from "molecular treasure trove" to "intelligent engine", marking the company's entry into a new ...
2026-05-18 22:00
7891
Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial
- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - Preliminary Phase 1 data demonstrated rapid, deep, and sustained effects on key biomarkers for at least 8 weeks following a single dose, including pSTAT6...
2026-05-18 21:15
7376
Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
* Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®. * Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axill...
2026-05-18 21:00
4523
Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)
WILMINGTON, Del., May 18, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced the successful completion of cohort 1 dosing in a phase I clinical trial for a novel biparatopic antibody targeting Thymic...
2026-05-18 19:00
6827
Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B- Targeting Antibody Demonstrates Potential to Become a Best-in-Class Therapy for Obesity CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical compan...
2026-05-18 08:03
4883
WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index
SHANGHAI, May 17, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Best-in-Class World Index (DJ BIC World Index, formerly Dow Jones Sustainability World Index), whic...
2026-05-18 08:00
3984
LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma
SEOUL, South Korea, May 17, 2026 /PRNewswire/ -- LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partn...
2026-05-18 08:00
3351
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
* RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerabilityto date. * Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors. MELBOURNE, Australia...
2026-05-15 22:25
9655
Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor patients SYDNEY, May 15, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, today ...
2026-05-15 19:06
5232
Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be presented as an oral presentation at the 2026 European ...
2026-05-15 15:43
5853
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'
SEONGNAM, South Korea, May 14, 2026 /PRNewswire/ -- SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer ag...
2026-05-15 07:03
4604
DeepQure Reports Encouraging Clinical Data from World's First Extravascular RDN System at AUA 2026
WASHINGTON, May 14, 2026 /PRNewswire/ -- DeepQure, a clinical-stage medical device company, announced the completion of its featured presentation at the American Urological Association (AUA) Innovation Nexus Forum, held during the AUA Annual Meeting. DeepQure was selected to present the clinical ...
2026-05-15 02:30
4086
OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer
PRINCETON, N.J., May 14, 2026 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company developing differentiated oncology therapies designed to translate cutting-edge innovation into clinically meaningful outcomes for patients, today announced the appointment of Antho...
2026-05-14 21:00
3544
Origin Agritech to Hold Business Update & First Half Fiscal Year 2026 Earnings Conference Call on May 22 at 8 a.m. ET
BEIJING, May 14, 2026 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, will announce its financial results for the first half of fiscal year 2026 on Thursday, May 21. Origin will host a conference call on Friday, M...
2026-05-14 20:00
6794
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 280 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
14322
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12990
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
12140
